Autologous HER2-CAR cytomegalovirus (CMV) bispecific T-cell therapy for patients with progressive GBM has demonstrated safety, with cells persisting in peripheral blood for 12 weeks and clinical benefits observed in 33% of patients. The gene discussed is ERBB2; the disease is glioblastoma.